NVS
Novartis AG
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Novartis AG
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Closest co-movers of Novartis AG; it has no SEC industry code.
Closest co-movers of Novartis AG; it has no SEC industry code.
Closest co-movers · 500d
GSKGSK×0.72r 0.64AMGNAmgen×0.71r 0.61PFEPfizer×0.63r 0.56JNJJohnson & JohnsonExpected move
No implied move.
Annual filing, covered
20-F parsed · Feb 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Feb 4 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG
164.53
+5.27 · +3.31%
Linked news
News
| Manager | Value | % base | |
|---|---|---|---|
| Fisher | $2.4B | 10.91% | +11.79% |
| Morgan Stanley | $1.4B | 6.13% | +2.34% |
| Dimensional | $1.3B | 5.71% | +0.09% |
| Primecap | $1.0B | 4.63% | −12.89% |
| Loomis Sayles & Co L P | $821.1M | 3.68% | −3.44% |
| Manager | Value | % base | |
|---|---|---|---|
| Fisher | $2.4B | 10.91% | +11.79% |
| Morgan Stanley | $1.4B | 6.13% | +2.34% |
| Dimensional | $1.3B | 5.71% | +0.09% |
| Primecap | $1.0B | 4.63% | −12.89% |
| Loomis Sayles & Co L P | $821.1M | 3.68% | −3.44% |